Aprea Therapeutics reported a net loss of $11.7 million for the nine months ended September 30, 2026, compared to a $10.1 million loss in the prior year period, driven primarily by increased research and development expenses. The company significantly strengthened its liquidity, ending the period with $37.8 million in cash and cash equivalents following equity financing activities.
Aprea Therapeutics reported third quarter 2026 financial results and provided a clinical update on its oral WEE1 inhibitor, APR-1051. The company expanded its Phase 1 clinical trial network to nine sites and expects to select a dose for the optimization phase of the study in the first half of 2027.
“We continue to make meaningful progress in advancing APR-1051 towards our goal of developing a differentiated, potentially best-in-class WEE1 inhibitor for patients with biomarker defined cancers.”
Oren Gilad, Ph.D., President and Chief Executive Officer
“With $37.8 million in cash and cash equivalents as of September 30, 2026, and an expected cash runway into the first quarter of 2028, we believe we are well positioned to execute our clinical development strategy, achieve meaningful milestones, and create long-term value for patients and shareholders.”
Oren Gilad, Ph.D., President and Chief Executive Officer